博九娱乐网

Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck鈥檚 proprietary Agonist Redirected Checkpoint, ARC庐, platform simultaneously inhibit checkpoint molecules and activate costimulatory…More molecules with a single therapeutic. The company鈥檚 lead SL-172154 (SIRP伪-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN鈩�, platform, which is designed to bridge gamma delta T cells to cell-based antigens for the treatment of patients with cancer and autoimmune disease. Shattuck has offices in both Austin, Texas and Durham, North Carolina.